China Pharma Begins First Work On Producing H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive SummaryChina's Hualan Biological Engineering says it has begun producing a solution aimed at creating a vaccine against the H1N1 flu virus. The company said it began work just hours after receiving seed viruses from the World Health Organization. Hualan is the only company certified in China to produce a pandemic vaccine, but 10 makers of seasonal-flu vaccines also are expected to receive the seed viruses. The head of SFDA's biology production office said the first batch of vaccines is expected to be produced as early as late July. The WHO has yet to decide whether the H1N1 flu virus is seasonal or pandemic. (Click here for more
You may also be interested in...
Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.
Denmark is moving to a QALY based evaluation system for hospital drugs. Despite a more complex process, the change could still mean quicker market access, says the pharmaceutical industry.